Zai Lab CEO Saman­tha Du is rais­ing a $150M biotech fund

Shang­hai-based Zai Lab isn’t just work­ing on its own pipeline of drugs any­more. CEO Saman­tha Du, a Pfiz­er vet who helped start Hutchi­son MediPhar­ma, has out­lined plans to raise $150 mil­lion for a new ven­ture fund of her own.

De­tails are hard to come by, but Du filed the pa­per­work on the ven­ture fund with the SEC last week.

Over the past year, Zai Lab ex­e­cut­ed a string of re­gion­al de­vel­op­ment pacts with Tesaro (ni­ra­parib), GSK (un­named an­ti-in­flam­ma­to­ry drugs) and Paratek (omada­cy­cline), which were fed in­to a pipeline that now has sev­en pro­grams un­der­way. The biotech has al­so launched dis­cov­ery work with in­ves­ti­ga­tors at Ts­inghua Uni­ver­si­ty. And a lit­tle more than a year ago the com­pa­ny raised $100 mil­lion in ven­ture cash.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.